- About the College
- Veterinary Medical Center
- Departments & Offices
The goal of this study is to determine whether the addition of radiation therapy to Palladia will result in a higher likelihood of tumor shrinkage, and/or a longer duration of improvement.
Mast cell tumor is a common skin tumor of dogs. Current treatment options available for mast cell tumor include various combinations of surgery, chemotherapy drugs such as vinblastine or lomustine, radiation therapy, and the new oral mast cell tumor drug Palladiaïƒ’ (toceranib). Palladia is an oral drug which works by inhibiting the function of a protein important for mast cell survival called KIT. Large studies have demonstrated that Palladia can be effective for some canine mast cell tumors. However, most mast cell tumors treated with Palladia do not go away completely, and improvement with Palladia is not permanent. Through this clinical trial, we hypothesize that the combination of Palladia and hypofractionated radiation therapy will be well tolerated and efficacious.
To qualify for enrollment in this study, dogs must:
Initially your dog will undergo a series of diagnostic tests, which may include blood tests, urinalysis, a fine needle aspirate of the lymph node draining the tumor area, and ultrasound examination of the abdomen. The results of these initial staging tests will determine if your dog is eligible to enter this clinical trial. These tests are part of the routine testing done in mast cell tumor patients, and may be performed even if you decide that your dog will not participate. Blood will be collected for study-related testing. Your dog will be sent home with medications to prevent side effects (Benadryl, pepcid/omeprazole, and prednisone), and Palladia, which will be started 3 days later on a M-W-F schedule. One week following the start of Palladia, your dog will return for a series of 3 or 4 weekly radiation treatments that will be delivered 6-8 hours post Palladia dosing. Regular rechecks will be performed after the completion of radiation therapy.
Dr. Cheryl London, clinicaltrials [at] cvm [dot] osu [dot] edu, for further information.